Ben Kiefel

Ben Kiefel is an accomplished leader in the biotechnology field, currently serving as CEO of Psaio Tx since March 2024 and as Co-Founder of Hula Therapeutics since May 2021. Additionally, Ben Kiefel has been the COO of Myrio Tx since January 2010, where the focus is on finalizing the development of the innovative protein display platform, ReD (Retained Display). Prior experience includes roles as COO and Research Officer at Alchemy Biosciences from September 2006 to January 2010. Ben Kiefel holds a Doctor of Philosophy (PhD) in Evolutionary Biology from Deakin University, earned from 2001 to 2006.